## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 6.29 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($367.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Boston Trust Walden Corp Sells 171,941 Shares of Waters Corporation $WAT**
- Source: MarketBeat | 20251230T100856 | Neutral | Relevance: 100%
- Boston Trust Walden Corp reduced its stake in Waters Corporation (NYSE:WAT) by 58.4%, selling 171,941 shares, and now owns 122,384 shares worth $36.69 million. Other institutional investors like Vanguard Group Inc., Alliancebernstein L.P., and State Street Corp have adjusted their positions in the medical instruments supplier. Waters Corporation's stock has a market capitalization of $22.96 billion and a P/E ratio of 35.44, with analysts giving it a "Moderate Buy" consensus rating.

**2. Danaher stock beats Wall Street dip as investors eye Fed minutes and Jan. 28 earnings**
- Source: ts2.tech | 20251230T035115 | Neutral | Relevance: 64%
- Danaher (NYSE:DHR) stock showed resilience, rising 0.1% to $230.63, outperforming major U.S. indexes during a thin year-end trading session as investors anticipate the Federal Reserve’s December meeting minutes and Danaher’s Q4 2025 earnings call on January 28. The stock's performance is notable given the broader market decline and upcoming economic catalysts, with traders also watching for updates on order trends and margins during the earnings report.

**3. Feld, Becton Dickinson EVP, sells $14509 in stock By Investing.com**
- Source: Investing.com Nigeria | 20251229T120808 | Somewhat-Bullish | Relevance: 62%
- Michael Feld, EVP at Becton Dickinson & Co, sold 74 shares of common stock totaling $14,509 on December 26, 2025. This sale was conducted under a Rule 10b5-1 trading plan. Becton Dickinson & Co (NYSE: BDX) has a history of 55 consecutive years of dividend payments and is set to report earnings on January 29, 2026.

**4. Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical**
- Source: Nasdaq | 20251230T110828 | Somewhat-Bullish | Relevance: 58%
- The medical instruments industry is experiencing a transformative shift due to generative AI (genAI) and ongoing M&A trends, despite global economic slowdowns and supply chain issues. Companies like Veracyte, IDEXX Laboratories, and Intuitive Surgical are adapting well to these changes by leveraging innovative technologies and strategic initiatives, leading to an uptrend in their stock prices. The industry's near-term outlook remains challenging due to various economic headwinds, but individual companies with strong earnings potential are positioned for growth.

**5. Feld, Becton Dickinson EVP, sells $14509 in stock By Investing.com**
- Source: Investing.com Australia | 20251229T111608 | Neutral | Relevance: 57%
- Michael Feld, EVP of Becton Dickinson & Co (NYSE:BDX), sold 74 shares of common stock totaling $14,509 on December 26, 2025, under a predetermined trading plan. Despite this insider sale, the company has a strong dividend history and is actively expanding its diagnostics portfolio and strategic partnerships.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $415 | $385 | +8% |
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.3x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +1.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.29 signals overvaluation risk, limited margin of safety. Forward P/E 26.8x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (1 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.9B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.29 |
| Forward P/E | 26.8 |
| Current P/E | 29.3 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.4% to 0.1% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-1.25), momentum weakening. RSI neutral at 51. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.14% (CS: 64) | Neutral |
| RSI_14 | 50.8 | Neutral |
| MACD Histogram | -1.25 | Bearish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 1.131x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $383.89
- **Stop Loss:** $367.63 (4.2% risk)
- **Target:** $400.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $31,095.09
- **Portfolio %:** 31.10%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*